Early treatment, soon after infection, reduces HIV transmissions and benefits patients. The Transmission Reduction Intervention Project (TRIP) evaluated a network intervention to detect individuals recently infected (in the past 6 months). TRIP was conducted in Greece (2013–2015) and focused on drug injector networks. Based on HIV status, testing history, and the results of an assay to detect recent infections, TRIP classified drug injector “Seeds” into groups: Recent Seeds (RS), and Control Seeds with Long-term HIV infection (LCS). The network members of RS and LCS were traced for two steps. The analysis included 23 RS, 171 network members of the RS, 19 LCS, and 65 network members of the LCS. The per-seed number of recents detected in the network of RS was 5 times the number in the network of LCS (Ratio RS vs. LCS: 5.23; 95% Confidence Interval (CI): 1.54–27.61). The proportion of recents among HIV positives in the network of RS (27%) was approximately 3 times (Ratio RS vs. LCS: 3.30; 95% CI: 1.04–10.43) that in the network of LCS (8%). Strategic network tracing that starts with recently infected persons could support public health efforts to find and treat people early in their HIV infection.

No abstract

Aims To project the impact of scaling up oral antiviral therapy and harm reduction on chronic hepatitis C (CHC) prevalence and incidence among people who inject drugs (PWID) in Greece, to estimate the relationship between required treatment levels and expansion of harm reduction programs to achieve specific targets and to examine whether hepatitis C viruse (HCV) elimination among PWID is possible in this high prevalence setting. Design A dynamic discrete time, stochastic individual-based model was developed to simulate HCV transmission among PWID incorporating the effect of HCV treatment and harm reduction strategies, and allowing for reinfection following treatment. Setting/Participants The population of 8,300 PWID in Athens Metropolitan area Measurements Reduction in HCV prevalence and incidence in 2030 compared with 2016. Findings Moderate expansion of HCV treatment (treating 4%–8% of PWID/year), with simultaneous increase of 2%/year in harm reduction coverage (from 44% to 72% coverage over 15 years), was projected to reduce CHC prevalence among PWID in Athens by 46%–90% in 2030, compared with 2016. CHC prevalence would reduce below 10% within the next 4–5 years if annual HCV treatment numbers were increased up to 16%–20% PWID/year. The effect of harm reduction on incidence was more pronounced under lower treatment rates. Conclusions Based on theoretical model projections, scaled-up hepatitis C virus (HCV) treatment and harm reduction interventions could achieve major reductions in HCV incidence and prevalence among people who inject drugs (PWID) in Athens, Greece by 2030. Chronic hepatitis C could be eliminated in the next 4–5 years by increasing treatment to more than 16% of PWID per year combined with moderate increases in harm reduction coverage.

Kainic acid injections into the nucleus accumbens in rats induced severe loss of neuronal perikarya and the presence of gliosis in its vicinity, without affecting more distant areas. Spontaneous locomotor activity was elevated in the lesioned rats. After a low dose of d-amphetamine (1.5 mg/kg) no significant differences in locomotor activity were found between lesioned and sham-operated rats, while the increase in locomotor activity normally induced by a moderate dose of apomorphine (1 mg/kg) was blocked in lesioned rats. These results indicate that although dopamine receptors on the nucleus accumbens neurons are involved in the mechanisms mediating locomotor behaviour, the locomotor stimulant effect of d-amphetamine is not exclusively dependent on intra-accumbens dopaminergic activity.

No abstract